Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
Gemcitabine-based chemotherapy is the current standard treatment for biliary tract cancers (BTCs) and resistance to gemcitabine remains the clinical challenge. <i>TP53</i> mutation has been shown to be associated with poor clinicopathologic characteristics and survival in patients with BTCs, indicat...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI AG
2020-10-01
|
| Sarja: | Biomolecules |
| Aiheet: | |
| Linkit: | https://www.mdpi.com/2218-273X/10/11/1474 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|